NCT03821792 2026-04-15
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07002320 2026-04-15
ASpiRE
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT05960578 2026-04-14
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06931340 2026-04-07
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03436654 2026-03-27
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06832774 2026-03-25
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT03088124 2026-03-20
PC-ARN
Institut Paoli-Calmettes
Phase 2 Completed
NCT03412396 2026-03-19
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting